The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
Official Title: Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
Study ID: NCT02042326
Brief Summary: The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM). Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.
Detailed Description: Anti-proliferative and anti-angiogenic properties of Sirolimus (Rapamycin®) are the basis of the rationale to use it in the treatment of arteriovenous malformations, for which the pathophysiology remains poorly understood. The interest of this class of drug is that inhibition of mTOR (mammalian target of rapamycin) may also block growth and / or angiogenic factors (other than VEGF) involved in the development of AVM. More specifically anti-VEGF drugs does not have that potential.
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCL, Bruxelles, , Belgium
CHU Amiens, Amiens, , France
CHU Bordeaux, Bordeaux, , France
CHU Dijon, Dijon, , France
CHRU Lille, Lille, , France
HCL Lyon, Lyon, , France
APHM, Marseille, , France
CHU Montpellier, Montpellier, , France
CHU Nancy, Nancy, , France
CHU Nice, Nice, , France
APHP, Paris, , France
CHU Strasbourg, Strasbourg, , France
CHU Tours, Tours, , France
Name: Bernard DEVAUCHELLE, MD, PhD
Affiliation: CHU Amiens
Role: STUDY_DIRECTOR
Name: Emmanuel MORELON, MD, PhD
Affiliation: HCL Lyon
Role: STUDY_CHAIR